Is there a Bearish outlook for Quest Diagnostics Incorporated (NYSE:DGX) this week?

Quest Diagnostics Incorporated (NYSE:DGX) Logo
Investors sentiment decreased to 1.12 in 2019 Q2. Its down 0.10, from 1.22 in 2019Q1. It turned negative, as 32 investors sold Quest Diagnostics Incorporated shares while 169 reduced holdings. 59 funds opened positions while 166 raised stakes. 115.81 million shares or 0.76% less from 116.69 million shares in 2019Q1 were reported.
Macquarie Ltd accumulated 1.4% or 7.95 million shares. M&T Retail Bank has 0.01% invested in Quest Diagnostics Incorporated (NYSE:DGX). New Mexico Educational Retirement Board invested 0.05% in Quest Diagnostics Incorporated (NYSE:DGX). Moreover, Leavell Management has 0.08% invested in Quest Diagnostics Incorporated (NYSE:DGX) for 7,399 shares. Seizert Cap Partners Ltd invested in 169,115 shares. Foster Motley invested in 4,826 shares or 0.07% of the stock. Nomura Asset Mngmt Communications Ltd reported 28,006 shares. Auxier Asset Mngmt has 0.79% invested in Quest Diagnostics Incorporated (NYSE:DGX) for 39,070 shares. Cypress Group has invested 0.07% in Quest Diagnostics Incorporated (NYSE:DGX). Baldwin Brothers Incorporated Ma holds 0.01% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX) for 400 shares. United Services Automobile Association stated it has 0.03% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX). John G Ullman Inc has 0.85% invested in Quest Diagnostics Incorporated (NYSE:DGX). Lazard Asset Ltd Co owns 1,707 shares. 3,158 were reported by Quantitative Systematic Strategies Limited Liability Co. Horizon Invests Limited Liability Com has invested 0.01% in Quest Diagnostics Incorporated (NYSE:DGX).

Quest Diagnostics Incorporated (NYSE:DGX) Ratings Coverage

Among 6 analysts covering Quest Diagnostics (NYSE:DGX), 2 have Buy rating, 1 Sell and 3 Hold. Therefore 33% are positive. Quest Diagnostics has $12100 highest and $8500 lowest target. $105.50’s average target is 1.05% above currents $104.4 stock price. Quest Diagnostics had 15 analyst reports since March 16, 2019 according to SRatingsIntel. Credit Suisse maintained Quest Diagnostics Incorporated (NYSE:DGX) rating on Wednesday, July 24. Credit Suisse has “Neutral” rating and $10500 target. The firm earned “Buy” rating on Wednesday, July 24 by Canaccord Genuity. Morgan Stanley maintained the shares of DGX in report on Wednesday, July 24 with “Overweight” rating. The stock has “Neutral” rating by JP Morgan on Wednesday, July 24. As per Friday, August 23, the company rating was maintained by Morgan Stanley. The rating was maintained by Morgan Stanley with “Overweight” on Thursday, April 25. UBS maintained the stock with “Neutral” rating in Wednesday, April 24 report. The firm has “Buy” rating given on Wednesday, April 24 by Canaccord Genuity. Goldman Sachs downgraded it to “Sell” rating and $8500 target in Monday, July 15 report. Below is a list of Quest Diagnostics Incorporated (NYSE:DGX) latest ratings and price target changes.

23/08/2019 Broker: Morgan Stanley Rating: Overweight Old Target: $111.0000 New Target: $121.0000 Maintain
24/07/2019 Broker: JP Morgan Rating: Neutral Old Target: $100.0000 New Target: $111.0000 Maintain
24/07/2019 Broker: Morgan Stanley Rating: Overweight Old Target: $104.0000 New Target: $111.0000 Maintain
24/07/2019 Broker: Canaccord Genuity Rating: Buy Old Target: $108.0000 New Target: $112.0000 Maintain
24/07/2019 Broker: Credit Suisse Rating: Neutral Old Target: $99.0000 New Target: $105.0000 Maintain
15/07/2019 Broker: Goldman Sachs Old Rating: Neutral New Rating: Sell Old Target: $90.0000 New Target: $85.0000 Downgrade
25/06/2019 Broker: Deutsche Bank Rating: Hold Maintain
10/05/2019 Broker: BidaskScore Rating: Sell Upgrade
25/04/2019 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $98.0000 New Target: $104.0000 Maintain
24/04/2019 Broker: UBS Rating: Neutral Old Target: $91.0000 New Target: $99.0000 Maintain

The stock decreased 0.54% or $0.57 during the last trading session, reaching $104.4. About 795,229 shares traded. Quest Diagnostics Incorporated (NYSE:DGX) has declined 4.62% since September 13, 2018 and is downtrending. It has underperformed by 4.62% the S&P500.

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company has market cap of $14.06 billion. The companyÂ’s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, gene and esoteric testing, and drugs-of-abuse testing, as well as anatomic pathology services, and related services and insights. It has a 19.69 P/E ratio. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum, and Care360 brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, and phlebotomists in physician offices.

More notable recent Quest Diagnostics Incorporated (NYSE:DGX) news were published by: which released: “Is Quest Diagnostics Incorporated (NYSE:DGX) Better Than Average At Deploying Capital? – Yahoo Finance” on July 24, 2019, also with their article: “Quest Diagnostics Q2 2019 Earnings Preview – Seeking Alpha” published on July 22, 2019, published: “Is Quest Diagnostics Incorporated’s (NYSE:DGX) CEO Salary Justified? – Yahoo Finance” on May 31, 2019. More interesting news about Quest Diagnostics Incorporated (NYSE:DGX) were released by: and their article: “Is Quest Diagnostics Incorporated (NYSE:DGX) A Smart Pick For Income Investors? – Yahoo Finance” published on June 18, 2019 as well as‘s news article titled: “Stocks To Watch: Apple, IPOs And German Auto – Seeking Alpha” with publication date: September 07, 2019.

Quest Diagnostics Incorporated (NYSE:DGX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.